Alpha-lipoic acid is sold worldwide as a general antioxidant supplement, and in Japan it has been used in weight-management and beauty products since the mid-2000s. It is also the ingredient behind one of the more unusual safety findings in the supplement literature, a rare autoimmune reaction that Japanese case reports were first to describe.
This guide covers what meta-analyses of controlled trials show for body weight and safety, the conditions Japan attaches to using the ingredient in foods, the autoimmune reaction Japanese clinicians identified, and how to formulate the ingredient responsibly.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning an alpha-lipoic acid product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2017 meta-analysis of 10 randomised, placebo-controlled trials found a small but statistically significant short-term weight-loss effect from alpha-lipoic acid supplementation.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Meta-analysis, Obesity Reviews 2017, 18(5):594–601 (PMID 28295905) | 10 randomised, double-blind, placebo-controlled trials of alpha-lipoic acid and weight | Mean weight loss 1.27 kg greater than placebo (95% CI 0.25–2.29 kg); mean BMI difference 0.43 kg/m² versus placebo; described as small but significant short-term weight loss, with dose showing no significant impact on the outcome and study duration affecting BMI change more than weight change |
| Safety meta-analysis, Antioxidants 2020, 9(10):1011 (PMID 33086555) | 71 randomised, placebo-controlled studies with 4,749 participants | Alpha-lipoic acid was not associated with an increased risk of any treatment-emergent adverse event compared with placebo |
Caveats worth keeping in view:
- The effect size is small — just over a kilogram on average — and the review’s own authors called it small, not a substantial result.
- Short-term only. The trials pooled were short-term studies; the authors noted further research was needed on dose and long-term benefit.
- Pooled trials cannot rule out rare reactions. The safety meta-analysis found no increase in adverse events across 71 trials, but trials of this size are not designed to detect a reaction as rare as the one described below.
- Ten trials is a limited evidence base, and results are inconsistent across the wider alpha-lipoic acid literature, which the review’s authors themselves noted before their analysis.
Checked against the published abstracts on 13 October 2026.
A safety finding first identified in Japan
Alpha-lipoic acid has been linked in case reports, first published in Japan, to a rare autoimmune reaction called insulin autoimmune syndrome, most often in people carrying specific HLA genetic markers common in East Asian populations, and Japan’s health ministry asks manufacturers to limit the amount and to caution consumers.
Insulin autoimmune syndrome is a rare condition in which the body produces antibodies against its own insulin, which can cause unpredictable episodes of low blood sugar. It was first described in Japan in 1970, well before alpha-lipoic acid supplements existed, and is generally associated with exposure to sulfhydryl-group-containing compounds, a chemical class that includes alpha-lipoic acid. A 2007 Japanese case report was among the first to propose alpha-lipoic acid as a possible trigger, describing a woman who developed the syndrome after taking an alpha-lipoic acid supplement, with no prior insulin exposure. Additional cases, in Japan and elsewhere, followed.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has addressed this in two notices. A November 2004 notice (Shokuan-Kihatsu No. 1105001), which lists thioctic acid (alpha-lipoic acid) among the substances handled as foods, adds a note: because thioctic acid is a prescription medicine in Japan, given by injection at 10–25 mg once a day, food businesses must take care to avoid excessive intake and give consumers appropriate information. An April 2010 notice to the health-food industry (Shokuan-Kihatsu 0423 No. 5) reported that a nationwide survey of 187 patients with spontaneous low blood sugar had found 19 taking “health foods”, 16 of them alpha-lipoic acid. It asked manufacturers to keep the alpha-lipoic acid content of their products below the maximum oral intake set for medicines, and to advise consumers to stop taking the product and consult a doctor if they notice cold sweats, trembling hands and feet or similar changes.
Case reports and subsequent research have noted that most identified cases carry specific HLA gene variants: HLA-DRB104:06 in East Asian patients and HLA-DRB104:03 in Caucasian patients are the variants most consistently reported. The 2010 notice attributes the concentration of reported cases in Japan to the HLA-DRB1*0406 type being more common among Japanese people than in Western populations. This means the reaction appears concentrated in people with a particular genetic susceptibility, rather than occurring broadly across everyone who takes the ingredient, though the rarity of the syndrome makes population-level frequency difficult to establish precisely.
What this means in practice:
- This is a rare-event safety signal, not a common side effect. It has been identified through individual case reports rather than through a controlled trial showing a measured rate.
- No blood-sugar claim of any kind belongs on a food product, regardless of this reaction; that rule applies to alpha-lipoic acid the same as any other ingredient under the disclaimer at the top of this guide.
- This does not block Japanese manufacture, but it sets conditions. Alpha-lipoic acid remains usable in foods, and a Japanese factory will expect the amount per serving to respect the 2010 notice and the product to carry a consumer caution along the lines MHLW describes.
💬 Need an evidence summary for your regulatory adviser that covers both the weight-loss meta-analysis and the autoimmune-syndrome case reports? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe alpha-lipoic acid by what has been studied, at the dose studied, without touching blood-sugar language.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for body weight alongside diet and activity, short-term" | "Burns fat” or long-term weight-loss guarantees |
| ”Contains alpha-lipoic acid” with the amount per serving | Any blood-sugar, insulin or diabetes-related wording |
| A clear ingredient declaration so anyone with a relevant medical history can check with a doctor | Health claims that go beyond the small effect size the meta-analysis reported |
How alpha-lipoic acid is formulated
Alpha-lipoic acid is available as a racemic mixture or as the R-isomer alone, and it is sensitive to heat and light, so stability is the main formulation question.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Tablet or capsule | Standard format, protects against light exposure | Coating choice affects stability |
| Softgel | Improves handling of the R-isomer form | Higher cost than a standard tablet |
| Drink | Used in some Japanese beauty and metabolism drinks | Stability under heat processing needs testing |
Decisions that shape the specification:
- Isomer form. Racemic (R/S) alpha-lipoic acid and the R-isomer alone differ in cost and are studied to different extents; confirm which form matches the evidence you intend to reference.
- Amount per serving. Match the amount to the dose range used in the trials pooled by the meta-analysis you cite, and keep it below the maximum oral intake for medicines, as MHLW’s 2010 notice asks.
- Stability. Alpha-lipoic acid degrades with heat, light and moisture; packaging and processing need to account for this.
- Your market’s status for alpha-lipoic acid. Its status as a food ingredient, and any labelling requirements related to the autoimmune-syndrome finding, differ between countries. Confirm before you commit to a formula.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Alpha-lipoic acid (listed as thioctic acid) is on MHLW’s list of substances not treated as medicines unless medicinal claims are made, and has been handled as a food ingredient since at least November 2004, subject to the 2004 and 2010 notices on intake and consumer information. See the Japan-made supplement OEM page, and compare with our L-carnitine and CoQ10 guides.
Before you ask for a quotation
A factory can quote accurately once the amount, the isomer form, the companions and the packaging are fixed.
- Alpha-lipoic acid amount per serving and isomer form (racemic or R-isomer)
- Dosage form and stability plan for heat, light and moisture
- Companion ingredients and their amounts
- Packaging
- Consumer caution wording that reflects MHLW’s 2010 notice
- Countries you will sell in, and any labelling requirements there
- First order and annual volume
💬 Ready to design a Japan-made alpha-lipoic acid product? Send us the concept — amount, form, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does alpha-lipoic acid help with weight loss?
A 2017 meta-analysis of 10 randomised trials found a small but statistically significant short-term weight-loss effect (1.27 kg more than placebo on average). The authors described it as small, and noted the trials were short-term.
2. What is insulin autoimmune syndrome, and why is it linked to alpha-lipoic acid?
It is a rare condition where the body makes antibodies against its own insulin, causing unpredictable low blood sugar episodes. Japanese case reports, starting in 2007, were among the first to link it to alpha-lipoic acid supplements, and most identified cases carry specific HLA genetic markers.
3. Is this reaction common?
No, but it is taken seriously in Japan. It has been identified through case reports rather than a controlled study measuring a population rate, and appears concentrated in people with a particular genetic susceptibility. A 2010 Japanese survey found 16 alpha-lipoic acid users among 187 patients with spontaneous low blood sugar, which led MHLW to ask for dose limits and a consumer caution.
4. Can a Japanese factory still make an alpha-lipoic acid product?
Yes. Alpha-lipoic acid has been handled as a food ingredient in Japan since at least 2004. MHLW’s 2004 and 2010 notices ask manufacturers to avoid excessive amounts and to inform consumers, so these conditions shape the formula and the label rather than block manufacture.
5. What should I decide before asking for a quotation?
The isomer form (racemic or R-isomer), the amount per serving, the packaging and stability plan, and the countries you plan to sell in.
Sources: “Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials”, Obesity Reviews 2017, 18(5):594-601, PMID 28295905; “Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome”, Diabetes Research and Clinical Practice 2007, 75(3):366-367, PMID 16963149; “Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies”, Antioxidants 2020, 9(10):1011, PMID 33086555, PMC7603186; “Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking α-lipoic acid”, Clinical Endocrinology 2014, 81(2):204-209, PMID 24111525; Japan Ministry of Health, Labour and Welfare, notice Shokuan-Kihatsu No. 1105001 (5 November 2004), note 5 on thioctic acid; MHLW notice Shokuan-Kihatsu 0423 No. 5 (23 April 2010) on health foods containing alpha-lipoic acid; MHLW Q&A on alpha-lipoic acid; MHLW list of substances not treated as medicines unless medicinal claims are made (Annex 2, updated 5 August 2026). Checked on 13 October 2026.